BRÈVE

sur Indivumed GmbH

Indivumed and University of Rochester expand cancer research collaboration

Indivumed GmbH and the University of Rochester Medical Center (URMC) are joining forces to enhance precision oncology. The collaboration builds on Indivumed's tissue and clinical data collection methods to accelerate novel cancer therapeutics development. This partnership focuses on high-need cancer stages such as colorectal, pancreatic, lung, and breast cancer.

Indivumed utilizes a platform that curates surgical tissue samples and clinical data, supporting cancer research and drug development. URMC's role in the collaboration includes gathering high-quality biosamples and clinical data under rigorous standards. The project emphasizes developing patient-derived tumor models to advance and validate pharmaceutical targets.

This collaboration aims to provide valuable insights and therapeutic guidance for participating clinicians. With URMC joining Indivumed's Global Clinical Network, this partnership marks a significant step in cancer therapeutics research.

R. P.

Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de Indivumed GmbH